• PRODUCTS
    • Assay Kit Platform & Formats
    • All Receptor Assays
    • Environmental Monitoring Assays
    • Growth Factor Assays
    • Ortholog Receptor Assays
    • Toxicology Assays
      • In Vitro Hepatotoxicity Assay Kit
      • Gene Expression Profiling Assay Kit
      • P-gp/MDR1 Drug Interaction Assay Kit
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
  • SERVICES
    • Reporter Assay Services
    • Nuclear Hormone Receptor Profiling
    • Environmental Monitoring Services
    • Gene Expression Profiling Services
    • In Vitro Hepatotoxicity Screening Services
    • Custom Assay Development
  • APPLICATIONS
    • Drug Discovery
    • Discovery Toxicology
    • Disease States
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Environmental Monitoring Applications
  • RESOURCES
    • Nuclear Receptor Overview
    • Webinars and Publications
      • New Research Publications
      • Webinars from INDIGO
      • Scientific Whitepapers from INDIGO
      • Scientific Posters from INDIGO
      • BLOG
    • Product Literature
      • INDIGO Technical Manuals
      • Product SDS
      • upcyte® Hepatocytes
    • FAQ
  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • CONTACT
    • Contact INDIGO
    • Request a Quote
    • Ordering & Distributors
Search site...

± α β γ δ Δ ε ζ κ ω ö ® ™ µ

  • PRODUCTS
    • Assay Kit Platform & Formats
    • All Receptor Assays
    • Environmental Monitoring Assays
    • Growth Factor Assays
    • Ortholog Receptor Assays
    • Toxicology Assays
      • In Vitro Hepatotoxicity Assay Kit
      • Gene Expression Profiling Assay Kit
      • P-gp/MDR1 Drug Interaction Assay Kit
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
  • SERVICES
    • Reporter Assay Services
    • Nuclear Hormone Receptor Profiling
    • Environmental Monitoring Services
    • Gene Expression Profiling Services
    • In Vitro Hepatotoxicity Screening Services
    • Custom Assay Development
  • APPLICATIONS
    • Drug Discovery
    • Discovery Toxicology
    • Disease States
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Environmental Monitoring Applications
  • RESOURCES
    • Nuclear Receptor Overview
    • Webinars and Publications
      • New Research Publications
      • Webinars from INDIGO
      • Scientific Whitepapers from INDIGO
      • Scientific Posters from INDIGO
      • BLOG
    • Product Literature
      • INDIGO Technical Manuals
      • Product SDS
      • upcyte® Hepatocytes
    • FAQ
  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • CONTACT
    • Contact INDIGO
    • Request a Quote
    • Ordering & Distributors

In Vitro Metabolism and CYP-Modulating Activity of Lavender Oil and Its Major Constituents

Print Friendly, PDF & Email

ABSTRACT

The application of essential oils has historically been limited to topical (massage therapy) and inhalational (aromatherapy) routes of administration. More recently, however, evaluation of the therapeutic effects of essential oils has expanded to include the oral route of administration, which increases the herb-drug interaction potential. The purpose of this study was to evaluate the herb-drug interaction potential of lavender essential oil and two of its primary phytoactive constituents, namely linalool and linalyl acetate. The metabolic stability of linalool and linalyl acetate was determined in human liver microsomes (HLM) and S9 fractions by quantitative analysis using UPLC-MS/MS system. Linalool was metabolically unstable in HLM and S9 fractions with an intrinsic clearance of 31.28 mL·min-1·kg-1, and 7.64 mL·min-1·kg-1, respectively. Interestingly, it was observed that linalyl acetate converted to linalool both in HLM and S9 fractions. Lavender oil showed weak inhibitory effect on the catalytic activity of CYP3A4 and CYP1A2 enzymes (IC50 12.0 and 21.5 µg/mL). Linalyl acetate inhibited CYP3A4 (IC50 4.75 µg/mL) while linalool did not show any inhibitory effect on any of the enzymes. The lavender oil and its constituents did not activate PXR to a considerable extent, and no activation of AhR was observed, suggesting a lack of potential to modify the pharmacokinetic and pharmacodynamic properties of conventional medications if used concurrently

To read the article click HERE.

Received: 25 October 2022 / Revised: 2 January 2023 / Accepted: 9 January 2023 / Published: 12 January 2023; Molecules

Author information:  Goutam Mondal (1), Olivia R Dale (1), Yan-Hong Wang (1), Shabana I Khan (1,2), Ikhlas A Khan (1,2), Charles R Yates (1)

(1) National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
(2) Division of Pharmacognosy, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.

Search site...
Click to Insert Symbols in Search

α β γ δ Δ ε ζ κ ® ™ µ

Request a Quote

Want More Information?

Resource Quick Links

  • Technical Manuals & Product Listing
  • Safety Data Sheets
  • Sample Study Report
  • Study Work Order Form

3006 Research Drive, Suite A1, State College, PA, USA 16801

+1 (814) 234-1919

  • Terms Conditions
  • Privacy Policy
  • Product Policies
  • Limited Use Disclosure

© 2022 INDIGO Biosciences, Inc. All Rights Reserved